Captopril is a potent, competitive angiotensin-converting enzyme (ACE) inhibitor widely indicated for the management of hypertension, congestive heart failure, and diabetic nephropathy. By inhibiting the… Read more

















Captopril is a potent, competitive angiotensin-converting enzyme (ACE) inhibitor widely indicated for the management of hypertension, congestive heart failure, and diabetic nephropathy. By inhibiting the enzyme responsible for converting angiotensin I into the vasoconstrictor angiotensin II, the drug facilitates systemic vasodilation. Pharmaceutical laboratories utilize Captopril reference standards—including pharmacopeial and non-pharmacopeial impurities—to conduct essential quality control, impurity profiling, and stability testing. These materials enable analysts to identify and quantify degradation products and synthetic by-products to ensure compliance with regulatory standards. Furthermore, stable isotope labelled compounds, such as deuterated variants, are critical for analytical method development and validation. These labelled analogs serve as precise internal standards in liquid chromatography-mass spectrometry (LC-MS/MS) workflows, allowing for the accurate quantification of analytes in complex matrices by effectively correcting for instrumental variability and matrix effects during rigorous pharmaceutical research and development.